CTEV at a glance
Claritev Corp (CTEV, SEC CIK 1793229) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Claritev Corp (CTEV) reported revenue of $965.4 million (up 3.7% from FY2024) and a net loss of $284.3 million. Diluted EPS was -$17.30.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Claritev Corp (CTEV) shares worth $70.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Klein Michael Stuart on November 12, 2026 of 20,067 shares at $27.07 per share.
- In the last 90 days, CTEV insiders reported 13 open-market purchases ($10.4M) and 6 open-market sales ($2.2M) on Form 4, a net purchase of $8.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $965.4M
- +3.7% vs prior year
- Insiders · 90 days
- 13 buys · 6 sells
- Net +$8.2M
- 13F holders
- 23 funds
- $70.0M · +1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- DOJ civil investigative demand received May 19, 2026, with inquiry ongoing after separate antitrust proceeding closure
- Regulatory risk: evolving healthcare laws may increase litigation exposure for cost management providers
- Legal risk: provider and member litigation increasingly multi-party, multi-claim, or class-wide
- Financial risk: uninsured or insufficiently insured litigation losses could materially affect results
Management Discussion & Analysis
- Revenue $268.3M, up 9.1% YoY from $246.0M
- Operating margin 7.7% vs 4.1% YoY, net loss $61.8M vs $69.8M
- Best segment: Claims intelligence revenue $192.5M, up 17.1%; worst: Payment and revenue integrity $25.9M, down 9.8%
- Cash balance $23.0M, operating cash flow $65.0M, investing outflow $128.8M
- Outlook: liquidity sufficient for next twelve months, with technology investments and antitrust legal expenses as headwinds
AI summary of the CTEV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for the quarter ended September 30, 2026 announced on November 9, 2026
- Detailed financial results and management commentary available in Exhibit 99.1, the earnings press release
Item EX-99.1: Item EX-99.1
- Q3 revenue $268.3M, up 9.1%, signaling continued growth across Claritev’s healthcare technology offerings
- Net loss narrowed to $61.8M from $69.8M, but interest expense remained substantial at $100.9M
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 11 to 12 directors, increasing governance capacity
- Jennifer Main appointed Class II director effective October 15, 2026
Item 7.01: Regulation FD Disclosure
- Claritev appointed Ms. Main to its Board of Directors
- Appointment signals a board-composition change, potentially affecting governance and strategic oversight
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Ben Letham appointed Class I director effective September 14, 2026, filling vacancy after John Prince’s passing
- Risk Committee appointment adds oversight responsibility
Item 7.01: Regulation FD Disclosure
- Claritev appointed Mr. Letham to its Board, adding a new director to corporate oversight
- Board appointment may affect governance, strategic direction and shareholder representation
AI summaries of CTEV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CTEV
Don't miss the next CTEV filing
- Alerts as it files. A push when CTEV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CTEV, by share count.
- Ask anything. An AI agent that reads every CTEV filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Klein Michael Stuart | Sell | Nov 12, 2026 | 20,067 | $27.07 |
| ARES MANAGEMENT LLC | Buy | Nov 11, 2026 | 13,587 | $28.73 |
| ARES MANAGEMENT LLC | Buy | Nov 11, 2026 | 13,587 | $28.73 |
| Dalton Travis | Buy | Nov 11, 2026 | 5,110 | $29.34 |
| Klein Michael Stuart | Sell | Nov 11, 2026 | 40,000 | $28.60 |
| Klein Michael Stuart | Sell | Nov 10, 2026 | 5,500 | $23.75 |
| ARES MANAGEMENT LLC | Buy | Nov 10, 2026 | 65,579 | $26.14 |
| ARES MANAGEMENT LLC | Buy | Nov 10, 2026 | 65,579 | $26.14 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $930.6M | $965.4M |
| Operating Income | $162.0M | -$1.4B | $28.8M |
| Net Income | - | -$1.6B | -$284.3M |
| Op. Margin | - | -149.4% | 3.0% |
| Net Margin | - | -176.9% | -29.4% |
| Balance Sheet | |||
| Total Assets | $7.0B | $5.2B | $4.9B |
| Equity | - | $84.0M | -$173.9M |
| ROE | - | -1958.8% | 163.5% |
| Per Share | |||
| EPS | $-0.14 | $-101.92 | $-17.30 |
| Cash Flow | |||
| Operating CF | - | $107.6M | $117.3M |
| CapEx | $108.9M | $118.1M | $129.6M |
Source: XBRL data in Claritev Corp (CTEV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CTEV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $70.0M |
| Q2 2026 | 22 | $80.9M |
| Q1 2026 | 22 | $34.7M |
| Q4 2025 | 24 | $108.2M |
| Q3 2025 | 20 | $113.6M |
| Q2 2025 | 22 | $90.0M |
| Q1 2025 | 17 | $23.8M |
| Q4 2024 | 10 | $14.5M |
- JPMorgan Chase & Co+349.6K (+8244%)
- Vanguard Capital Management LLC+163.1K (+39%)
- Bank of America Corp+85.4K (+91%)
- Goldman Sachs Group+82.9K (+307%)
- Morgan Stanley+70.1K (+327%)
- Invesco Ltd−53.9K (-72%)
- Wells Fargo & Co−6.2K (-74%)
- Citigroup−2.4K (-7%)
- BNY Mellon−1.1K (-4%)
- U.S. Bancorp−2 (-1%)
- Two Sigma Investments+94.8K
- Citadel Advisors LLC+45.9K
- FMR LLC (Fidelity)−2.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 160 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CTEV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Oct 27, 2026 | - | - | - |
| 4 | Oct 27, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 4 | Aug 7, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 6, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
Related Information Technology companies
- ACN · AccentureServices-Business Services, NEC
- ACVA · ACV Auctions Inc.Services-Business Services, NEC
- ADV · Advantage Solutions Inc.Services-Business Services, NEC
- AKAM · Akamai TechnologiesServices-Business Services, NEC
- BABA · Alibaba Group Holding LtdServices-Business Services, NEC
- ALIT · Alight, Inc. / DelawareServices-Business Services, NEC
- CASS · CASS INFORMATION SYSTEMS INCServices-Business Services, NEC
- CBZ · CBIZ, Inc.Services-Business Services, NEC
CTEV SEC filings: frequently asked questions
Are CTEV insiders buying or selling?
In the last 90 days, Claritev Corp (CTEV) officers, directors and 10% owners reported 13 open-market purchases worth $10.4 million by 2 insiders and 6 open-market sales worth $2.2 million by 3 insiders on Form 4, a net purchase of $8.2 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CTEV stock?
As of September 30, 2026, the largest Claritev Corp (CTEV) holders among the 13F filers tracked by SignalX were BlackRock ($16.4 million), Vanguard Capital Management LLC ($12.4 million), Prudential Financial ($8.0 million), JPMorgan Chase & Co ($7.7 million), AQR Capital Management ($3.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CTEV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Claritev Corp (CTEV) reported revenue of $965.4 million (up 3.7% from FY2024) and a net loss of $284.3 million. Diluted EPS was -$17.30. The figures come from the XBRL data in the 10-K.
What did CTEV report in its latest 8-K?
Claritev Corp (CTEV) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for the quarter ended September 30, 2026 announced on November 9, 2026.
What are the latest CTEV SEC filings?
Claritev Corp (CTEV) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 16, 2026.
What is CTEV's SEC CIK number?
Claritev Corp (CTEV)'s SEC Central Index Key (CIK) is 1793229. EDGAR lists every CTEV filing under that number.
Ask anything about CTEV
The research agent reads CTEV's filings, financials, insider trades and 13F holders, then answers with sources.